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Abstract
Alginate lyase enzymes represent prospective biotherapeutic agents for treating bacterial infections, particularly in the
cystic fibrosis airway. To effectively deimmunize one therapeutic candidate while maintaining high level catalytic
proficiency, a combined genetic engineering-PEGylation strategy was implemented. Rationally designed, site-specific
PEGylation variants were constructed by orthogonal maleimide-thiol coupling chemistry. In contrast to random PEGylation
of the enzyme by NHS-ester mediated chemistry, controlled mono-PEGylation of A1-III alginate lyase produced a conjugate
that maintained wild type levels of activity towards a model substrate. Significantly, the PEGylated variant exhibited
enhanced solution phase kinetics with bacterial alginate, the ultimate therapeutic target. The immunoreactivity of the
PEGylated enzyme was compared to a wild type control using in vitro binding studies with both enzyme-specific antibodies,
from immunized New Zealand white rabbits, and a single chain antibody library, derived from a human volunteer. In both
cases, the PEGylated enzyme was found to be substantially less immunoreactive. Underscoring the enzyme’s potential for
practical utility, .90% of adherent, mucoid, Pseudomonas aeruginosa biofilms were removed from abiotic surfaces following
a one hour treatment with the PEGylated variant, whereas the wild type enzyme removed only 75% of biofilms in parallel
studies. In aggregate, these results demonstrate that site-specific mono-PEGylation of genetically engineered A1-III alginate
lyase yielded an enzyme with enhanced performance relative to therapeutically relevant metrics.
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Introduction
The major contributor to mortality in cystic fibrosis (CF)
patients is pulmonary infection by the Gram-negative bacterium P.
aeruginosa. The majority (,75%) of CF-associated P. aeruginosa
isolates exhibit a mucoid phenotype characterized by overpro-
duction of alginate, an exopolysaccharide component of the
biofilm matrix [1]. Bacterial alginate is one of the most studied P.
aeruginosa virulence factors [2], with confirmed roles in protection
of bacteria from host immune defenses [3,4], exacerbation of
inflammatory tissue damage [5], and contribution to bacterial
resistance towards conventional antibiotic therapies [6,7,8]. In
addition, alginate has been shown to increase the viscosity of
mucosal secretions contributing to respiratory tract obstructions
[9]. Considering its important role in the pathology of P. aeruginosa
infections of the CF lung, alginate represents an attractive target
for developing novel therapeutic agents for CF patients.
Alginate lyase enzymes (EC 4.2.2.3) efficiently degrade alginate
via b–elimination cleavage of glycosidic bonds in the polymer
backbone. Numerous observations support the hypothesis that
alginate lyases could be powerful therapeutic agents for treating
mucoid P. aeruginosa infections. For example, alginate lyases have
been shown to enhance phagocytosis of P. aeruginosa by human
macrophages [10], increase the susceptibility of P. aeruginosa to a
variety of antibiotic treatments [6,11,12,13], and decrease the
viscosity of CF sputum [14]. The latter activity suggests a
therapeutic application analogous to that of recombinant human
DNase (PulmozymeH), an inhaled enzyme therapy that degrades
extracellular DNA, aids in clearance of viscous airway obstructions,
and temporarily improves pulmonary function in CF patients [15].
Unfortunately, alginate lyases are invariably derived from non-
human sources, and their exogenous origins may predispose them
towards excessive immunogenicity in human patients. An immune
response against biotherapeutic agents can manifest a spectrum of
complications including increased rates of drug clearance, direct
inhibition of therapeutic activity, and varying degrees of allergic
reaction with the potential for life-threatening anaphylactic shock
[16]. There is an increasing awareness of the risks associated with
immune responses against biotherapeutic agents [17], and this
knowledge is prompting the restructuring of biotherapeutic
development strategies so as to address potential safety concerns
earlier in the process [18]. Considering the tremendous potential of
alginate lyase therapeutic agents, strategies to mitigate putative anti-
enzyme immune reactions merit examination.
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ene glycol (PEG) is a common approach for modulating
immunogenicity and stability [19]. Indeed, PEGylation of
Sphingomonas sp. A1-III alginate lyase (A1-III), one therapeutic
candidate, has been shown to reduce antibody binding in vitro [20].
Unfortunately, the random attachment of amine-reactive PEG
molecules to solvent exposed lysines of A1-III resulted in a
significant proportion of inactivated enzyme (.50% inactivation
with 10 of 12 formulations). Thus, while PEGylation can
successfully reduce the enzyme’s immunoreactivity, maintaining
a homogenous enzyme composition with high catalytic activity
necessitates a more controlled PEG-conjugation strategy.
To facilitate precise control over both the site of PEG
attachment and the extent of PEGylation, cysteine residues were
engineered into the A1-III enzyme at five different surface
accessible locations. These rationally substituted cysteine residues
provided an orthogonal chemical handle for site-specific PEGyla-
tion reactions using maleimide activated PEG. It was anticipated
that selective and controlled PEGylation would result in modified
variants simultaneously demonstrating high catalytic proficiency
and reduced immunoreactivity. In this study, solution phase
reaction kinetics, biofilm disrupting activity, and in vitro antibody
binding of genetically engineered PEG variants have been assessed
and compared to the non-PEGylated wild type enzyme control.
The results suggest that at least one modified enzyme meets or
exceeds the experimental objectives, and thereby possesses
enhanced potential as an antibacterial therapy.
Results
Construction of A1-III Mutants
To facilitate site-specific PEGylation, mutant A1-III genes
encoding single cysteine substitutions were constructed by total
gene synthesis [21]. The synthetic genes were codon optimized for
expression in E. coli, and each gene encoded a single site-specific
cysteine substitution: S32C, A41C, A53C, A270C or A328C,
where residue numbering is per Yoon et al. [22] The five sites for
mutation were selected based on an analysis of PDB structure
1HV6 [22]. Priority was placed on small amino acids that, when
substituted with a cysteine, would result in a solvent exposed thiol
group (Fig. 1 and Movie S1). Particular emphasis was given to
residues with spatial proximity to the S32-C49 peptide segment, a
motif that has previously been reported as constituting an
immunodominant region of the enzyme [23]. A C-terminal
hexahistidine tag (his-tag) was appended to each mutant to
facilitate purification by immobilized metal-ion affinity chroma-
tography (IMAC). A construct encoding the corresponding his-
tagged version of the wild type enzyme (WT-his) was generated as
a control.
Expression levels of the recombinant enzymes from a T7 driven
pET vector system varied moderately. Following overnight shake
flask induction, cell lysis, IMAC purification and dialysis, the WT-
his enzyme and high yielding variants such as A53C-his produced
upwards of 20 mg per liter of cell culture. In contrast, variant
A41C-his yielded 3-fold less protein under the same expression
conditions. Importantly, non-reducing SDS-PAGE gels showed
that the cysteine variants were isolated predominantly as
monomers. Only after extended storage were the genetically
engineered proteins found to dimerize via intermolecular disulfide
bond formation. Interestingly, the non-reducing SDS-PAGE
analysis also indicated that one or both of the protein’s two native
disulfide bonds (C49–C112 and/or C188–C189) were not fully
formed upon cell lysis and IMAC separation, but that oxidation to
the fully disulfide bonded state occurred during the first 24 to
48 hours after purification (data not shown). This observation is
consistent with expression of the enzymes in the reducing
environment of the E. coli cytoplasm and subsequent oxidation
by molecular oxygen following lysis and storage.
PEG Conjugation and Purification
Exposed thiol groups of the engineered cysteine residues were
conjugated to a 20 kDa methoxy-maleimide PEG. Reaction time,
temperature and stoichiometry were the subject of detailed
optimization studies, and it was ultimately determined that 1 hour
reactions at 25uC with a 5:1 molar ratio of PEG:enzyme typically
yielded maximal mono-PEGylated product, i.e., protein molecules
each bearing a single PEG polymer chain. Mono-PEGylated
reaction products were readily separated from unconjugated
protein by FPLC size exclusion chromatography (Fig. 2), and
optimized reactions typically produced 40 to 50% yields of .95%
pure material.
Enzyme Kinetics
Alginate depolymerization kinetics were assessed for the various
PEGylated enzymes and the WT-his control using brown seaweed
alginate (BSWA) as a model substrate. Michaelis constants (Km)
and maximum reaction velocities (Vmax) were determined by
nonlinear regression of initial velocities vs. substrate concentration.
All five of the PEGylated variants were found to possess catalytic
efficiencies (Vmax/Km) exceeding that of the corresponding WT-
his construct, although most exhibited a decrease of 2-fold or less
in Vmax (Table 1). Variant A41C-his-PEG was found to possess
particularly low maximum reaction velocities, and it was therefore
eliminated from further studies.
One modified enzyme, A53C-his-PEG, maintained Vmax values
similar to the WT-his control, and the activity of this variant was
examined in greater detail. To separate the effects of the point
mutation from the effects of PEGylation, the kinetics of A53C-his
Figure 1. Sites of cysteine substitution. Ribbon diagram of alginate
Lyase A1-III (PDB file 1HV6). A trisaccharide reaction product is bound in
the active cleft and shown as a grey ball and stick model. Amino acid
residues targeted for cysteine substitution are shown in space filling
mode, and are color coded as follows: S32C=Red, A41C=Orange,
A53C=Green, A270C=Yellow, and A328C=Purple.
doi:10.1371/journal.pone.0017042.g001
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The A53C amino acid substitution drove a reduction in both Vmax
and Km, but subsequent PEGylation produced a 60% increase in
Vmax restoring the variant’s maximum reaction velocity to wild
type levels while not altering the reduced Km value. The result was
an enzyme-PEG conjugate with a .2-fold improved catalytic
efficiency compared to WT-his.
Alginate biopolymer produced by mucoid P. aeruginosa patho-
gens differs from that produced by brown seaweed in that bacterial
alginate is partially acetylated at the C2 and C3 hydroxyls of
mannuronate residues [24]. To evaluate activity on the bacterial
substrate, alginate was purified from the mucoid P. aeruginosa
clinical isolate FRD1. The specific activities of WT-his and A53C-
his-PEG were determined using 0.1% (wt/vol) bacterial alginate.
Unexpectedly, the PEGylated variant exhibited a 1.8-fold
increased specific activity relative to the corresponding WT-his
construct (Fig. 3).
It is possible that the altered catalytic activities of the PEGylated
variants resulted from subtle structural perturbations to the
enzyme’s 3-dimensional fold. Such deviations from the native
structure might have undesired consequences that compromise the
potential for practical utility, e.g., decreasing enzyme stability
during long term storage. To assess the impact of PEGylation on
storage stability, the activity of A53C-his-PEG was followed during
more than two months of storage at 4uC. No loss of activity was
observed during the course of the 70 day experiment (data not
shown).
Antibody Binding and Immunogenicity
Polyclonal anti-A1-III IgG was purified by antigen affinity
chromatography of pooled serum from two New Zealand white
rabbits, which had both been immunized with the non-tagged,
native enzyme (WT). The EC50 of the polyclonal antibody was
determined for various PEGylated enzymes using standard ELISA
techniques, and these values were compared to that for the non-
PEGylated WT-his control. Genetically engineered variants S32C-
his-PEG, A53C-his-PEG, A270C-his-PEG and A328C-his-PEG
exhibited a 40–90% decrease in immunoreactivity relative to the
WT-his enzyme counterpart (Fig. 4). Together, the high catalytic
activity and decreased antibody binding of A53C-his-PEG
distinguished this enzyme as a particularly promising candidate.
To evaluate immunogenicity by a metric with greater relevance
to human patients, binding of a naı ¨ve human antibody repertoire
to both WT-his and A53C-his-PEG was assessed. Each protein
was biotinylated and immobilized at saturating mM surface
densities on streptavidin-coated magnetic beads. These alginate
lyase coated beads represent one of two key elements in the
immunogenicity assays. The second element is a yeast library
displaying 10
9 human scFv antibody fragments [25]. Yeast surface
display produces a high degree of scFv multivalency, and when
mixed with the alginate lyase coated beads, the resulting avid
interactions facilitate capture of low affinity binders likely present
in the human immune repertoire prior to affinity maturation. As a
result, yeast cells expressing an scFv that recognizes an epitope on
the candidate proteins are bound to the surface of the magnetic
beads. Following a pre-screen to remove non-specific binders, the
yeast library was incubated separately with either WT-his coated
beads or A53C-his-PEG coated beads. After binding of the library,
the beads were magnetically separated, unbound yeast in the
supernatant were removed by aspiration, and the beads were
resuspended in fresh buffer. An aliquot of this bead slurry was
serial diluted, plated on yeast growth media, and outgrown to
Figure 2. SDS-PAGE analysis of PEGylated variant production.
Samples run on a reducing 12.5% gel, and stained for total protein with
Coomassie brilliant blue. Lane 1: Bio-Rad Precision Plus Protein Ladder;
Lane 2: Whole cell lysate of non-expressing cells; Lane 3: Whole cell
lysate of induced cells; Lane 4: IMAC purified A53C-his; Lane 5: Crude
A53C-his PEGylation reaction product; Lane 6: Size exclusion FPLC
purified A53C-his-PEG; Lane 7: IMAC purified WT-his; Lane 8: FPLC
purified native WT.
doi:10.1371/journal.pone.0017042.g002
Table 1. Kinetic parameters for alginate degradation.
Enzyme
Vmax
[DA235 (min ? mg)
21]
Km
(mg/ml) Vmax/Km
WT-his 440630 80620 661
A53C-his 280630 30669 62
S32C-his-PEG 330620 26661 3 63
A41C-his-PEG 134637 . 1 60.8 1862
A53C-his-PEG 460650 40610 1364
A270C-his-PEG 300620 15652 0 67
A328C-his-PEG 180610 13641 4 64
Depolymerization of BSWA was followed by monitoring absorbance at 235 nm.
Kinetic parameters were determined by nonlinear regression of initial rate vs.
substrate concentration data (Prism version 4.0).
doi:10.1371/journal.pone.0017042.t001
Figure 3. Comparison of reaction kinetics with BSWA and
bacterial alginate. The specific activities of WT-his (white bars) and
A53C-his-PEG (black bars) were determined with a model alginate
substrate (BSWA) as well as with purified bacterial alginate (FRD1). The
two enzymes are equally active with BSWA at saturating concentrations,
but the PEGylated variant exhibits 80% faster kinetics with the bacterial
substrate (p,0.01), which is the ultimate therapeutic target. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0017042.g003
Engineered Alginate Lyase-PEG Conjugates
PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17042determine the number of colony forming units (cfu’s) that
remained bound to the beads. The washing and plating procedure
was repeated two additional times, and the number of bead-bound
yeast was determined for each wash step. The resulting cfu counts
provide a means to assess the relative reactivity of a human
antibody repertoire towards the two target proteins. Note that
each yeast colony represents a single human scFv antibody
fragment that specifically bound the target protein on the cognate
magnetic bead surface. Beads coated with the PEGylated enzyme
target were found to bind up to 13-fold fewer yeast cells than those
coated with the WT-his enzyme (Fig. 5a, wash 2). Because the
A53C-his and WT-his proteins are nearly identical in amino acid
sequence, the difference in binding counts indicates that the PEG
moiety effectively blocks interactions between human scFvs and
their corresponding immunogenic epitopes on the A1-III enzyme.
Bound yeast cells isolated during these initial experiments
represent enriched populations displaying scFvs that specifically
recognize epitopes of either WT-his or A53C-his-PEG. To assess
the cross-reactivity of the scFvs, yeast selected as binders to the
WT-his beads were propagated and employed in a second round
of binding experiments against both proteins in parallel. Likewise,
yeast that initially bound the A53C-his-PEG beads were similarly
tested for cross-reactivity. Importantly, yeast originally isolated as
binders to the WT-his enzyme had a reduced capacity to
recognize the PEGylated variant. Furthermore, yeast originally
isolated as binders to A53C-his-PEG more readily recognized the
WT-his protein then their original PEGylated target (Fig. 5b).
Collectively, this data set implies that, although the A1-III
enzyme’s human antibody epitopes have not been completely
occluded, PEGylation effectively reduces access to these sites. In
particular, site specific PEGylation of A1-III alginate lyase (i)
substantially reduced binding of naı ¨ve human antibody repertoires
(Fig. 5a), and (ii) blocked .50% of specific, human, anti-A1-III
scFv antibody fragments (Fig. 5b).
Biofilm Disruption Studies
There exists considerable evidence that P. aeruginosa grows in
biofilm communities during CF lung infection [26], and it is likely
that disrupting alginate biofilms represents a key challenge in the
fight to eradicate CF-associated P. aeruginosa infections. To assess
this therapeutically relevant aspect of enzyme function, biofilms of
the alginate-producing P. aeruginosa strain Xen5, a derivative of
clinical isolate ATCC 19660, were first established by growth in
96-well plates. Subsequently, adherent biofilms were treated for
one hour with 1 mg/ml of WT-his or A53C-his-PEG and then
washed to remove degraded biofilm. The remaining adherent
alginate biofilm matrix was quantified using a ConA lectin-HRP
conjugate that binds to mannuronate residues of alginate [27].
The percentage of biofilm removed by each enzyme was
Figure 4. Immunoreactivity by ELISA. The antibody concentration
required to achieve 50% maximum ELISA signal (EC50) was determined
for each enzyme using polyclonal anti-A1-III antibody purified from
rabbit immune serum. The results are reported as fractional immuno-
reactivity based on normalization with the WT-his enzyme, which was
included as an internal control in all experiments (see Experimental
Procedures). All of the PEGylated enzymes were found to exhibit
significantly reduced antibody binding relative to the WT-his control
(p,0.01 for each). Error bars represent standard deviation.
doi:10.1371/journal.pone.0017042.g004
Figure 5. Human antibody binding. The WT-his (white bars) and A53C-his-PEG (black bars) protein targets were biotinylated and captured on the
surface of streptavidin coated magnetic beads. A) The two bead preparations were independently incubated with a yeast surface displayed scFv
antibody library derived from human immune cells. Following binding, the beads were magnetically separated and washed three times. The number
of yeast that remained bound after each wash step was determined by plating serial dilutions of the resuspended beads and enumerating cfu’s. The
resulting yeast colonies represent human scFvs that specifically bound to the A1-III enzymes on the corresponding magnetic beads. A53C-his-PEG
coated magnetic beads bound up to 13-fold fewer human antibodies than did the WT-his coated beads (p,0.01 for each of the three washes). B)
Characterization of first round binders from both protein targets. Yeast isolated as binders to either WT-his or A53C-his-PEG were propagated and
subsequently incubated with magnetic beads bearing each protein target. For both yeast populations, the A53C-his-PEG coated beads (black bars)
bound at least 60% fewer cells than did the WT-his beads (white bars), a result that demonstrates PEGylation effectively blocked key immunogenic
epitopes (p,0.01 for all differences). Error bars represent standard deviation.
doi:10.1371/journal.pone.0017042.g005
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treatment. Both the wild type and PEGylated enzymes were found
to effectively remove the majority of established biofilm from the
wells (Fig. 6). Consistent with its enhanced solution phase activity
towards bacterial alginate, A53C-his-PEG exhibited a significant
(p=0.025) increase in mucoid biofilm disruption relative to the
WT-his protein (94% vs. 75% biofilm removal, respectively).
These results suggest that the enhanced catalytic performance of
the genetically engineered A53C-his-PEG enzyme may have
relevance to clinical applications.
Discussion
Biofilms are thought to play a key role in refractory P. aeruginosa
infections of the CF airway [26]. In particular, the transition of P.
aeruginosa to a mucoid phenotype is associated with alginate
overproduction, altered biofilm architecture, high level antibiotic-
resistance, and accelerated deterioration of lung function [1,8]. As
a consequence, inhaled alginate lyase enzymes could represent
powerful new therapies for treating CF lung infections. To realize
their therapeutic benefit in humans, however, the risks associated
with the putative immunogenicity of these heterologous enzymes
should be appropriately mitigated. It has been shown previously
that random PEGylation of free amines on the surface of A1-III
alginate lyase effectively blocked enzyme-specific antibody binding
[20]. Unfortunately, this strategy resulted in a significant loss of
catalytic proficiency, as most preparations exhibited .50%
reduction in alginate degrading activity. For a given PEG chain
length, the degree of inactivation was directly proportional to the
degree of de-immunization, a result that likely derived from the
stochastic nature of NHS-ester conjugation to protein surfaces.
To better leverage the de-immunizing properties of PEG, a site-
specific PEGylation strategy has been developed for the A1-III
enzyme. Several surface accessible residues of the native enzyme
were substituted with cysteines, and site-specific mono-PEGylation
of the genetically engineered variants was achieved using a
maleimide-activated 20 kDa PEG chain. Importantly, all of the
site-specific, mono-PEGylated variants examined here were found
to possess improved catalytic efficiency with a model substrate,
BSWA. Maximum catalytic activity, however, was found to be
critically dependent on the exact site of PEG attachment, as only
variant A53C-his-PEG was found to maintain a Vmax comparable
to that of the wild type enzyme control. This outcome underscores
a fundamental advantage of orthogonal conjugation chemistry: the
site and extent of protein modification can be precisely controlled
so as to yield a homogeneous enzyme preparation having
uniformly high functionality.
Of particular relevance to treatment of bacterial infections,
A53C-his-PEG was 80% more active than the WT-his control
when assayed against solutions of bacterial alginate. The
mechanistic origins of this enhanced activity on bacterial but not
BSWA are not entirely clear. It is possible that PEGylation simply
distorts the native enzyme structure so as to better accommodate
the bulkier, acetylated, bacterial alginate. An alternative explana-
tion, however, could relate to the acetylated alginate’s greater
hydrophobicity and increased extent of intermolecular interaction
[28]. A high degree of substrate-substrate interaction could reduce
enzyme accessibility to individual alginate chains and slow
substrate degradation relative to non-acetylated BSWA. The
amphipathic nature of PEG allows it to interact closely with both
hydrophilic and hydrophobic molecules [19], and this property
could facilitate insertion into amorphous higher-order structures of
acetylated bacterial alginate. We speculate that the PEG moiety of
A53C-his-PEG may disrupt enhanced substrate-substrate interac-
tions in the enzyme’s local environment, and thereby free
individual alginate chains for more efficient enzymatic degrada-
tion. Loose parallels might be drawn to cellulases and chitinases,
which efficiently degrade highly ordered, macromolecular,
carbohydrate substrates. To do so, these enzymes employ non-
catalytic binding domains that disrupt intermolecular polymer
packing and enhance access to individual substrate chains [29,30].
Certainly, this analogy should be approached with caution, as
alginate solutions are hydrogels as opposed to crystalline or semi-
crystalline substrates. None-the-less, site-specific PEGylation of
A1-III alginate lyase has yielded a functionally enhanced enzyme
that degrades bacterial alginate with greater efficiency.
In addition to maintaining high level catalytic activity, de-
immunization of the A1-III protein was a second critical design
objective of these experiments. The PEGylated constructs showed
a 60–90% reduction in immunoreactivity with rabbit anti-A1-III
IgG antibodies. Of greater relevance to human use, A53C-his-
PEG bound a substantially smaller fraction of a naı ¨ve human scFv
antibody library, relative to the non-PEGylated WT-his control.
Furthermore, human scFvs that specifically bound the WT-his
enzyme were 2.5-fold less likely to bind A53C-his-PEG. These
data suggest that site-specific PEGylation has yielded a general
reduction in the enzyme’s antibody reactivity, and the studies with
human antibody fragments lead us to hypothesize that the reduced
immunoreactivity could translate to the clinic.
In clinical applications of alginate lyases, high level solution-
phase activity may not be sufficient to affect a therapeutic benefit
in CF patients. Instead, the practical utility of alginate lyase
therapies will likely be defined by their capacity to disrupt mucoid
P. aeruginosa biofilms. During a one hour treatment, the modified
A53C-his-PEG enzyme removed more than 90% of established
biofilms, a .15% improvement over the non-PEGylated WT-his
protein. This enhanced ability to disrupt biofilms is consistent with
the improved solution-phase kinetics of the engineered enzyme,
and may stem from a similar mechanistic origin. While biofilms in
the human airway have properties distinct from those grown on
abiotic surfaces [26], the fact that A53C-his-PEG virtually cleared
Figure 6. Disruption of mucoid P. aeruginosa biofilms. Adherent
biofilms of a mucoid clinical isolate were established in 96-well plates
and subsequently treated with 1 mg/ml enzyme for 1 hour. Remaining
biofilm was then quantified using an alginate-sensitive lectin-HRP
conjugate and ABTS substrate. Signals were normalized to a buffer only
treatment. Both enzymes removed a significant proportion of biofilm
relative to the buffer control (p,0.01). Importantly, theA53C-his-PEG
enzyme removed .15% more biofilm than the WT-his enzyme
(p,0.025). Error bars represent standard deviation.
doi:10.1371/journal.pone.0017042.g006
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yield therapeutic benefits in the treatment of CF associated, P.
aeruginosa infections.
Materials and Methods
Oligonucleotides were purchased from IDT (Coralville, IA), and
were purified by standard desalting. The gene sequences for the
A1-III alginate lyase enzymes were derived from the wild type A1-
III enzyme encoded in the genome of Sphingomonas sp. A1
(GenBank: AB011415). Restriction enzymes, Phusion polymerase,
and T4 ligase were from New England Biolabs (Ipswich, MA), and
were used as directed by the manufacturer. Expression vector
pET28b was from Novagen (San Diego, CA). Plasmid purification
kits, Ni-NTA agarose and corresponding columns were from
QIAGEN (Valencia, CA). Gel extraction/DNA clean up kits were
from Zymo Research (Orange, CA). 20 kDa methoxy-maleimide
polyethylene glycol (PEG) was from JenKem Technology (Allen,
TX). A ¨KTA FPLC system and Superdex75 SEC resin were from
GE Healthcare Life Sciences (Piscataway, NJ). Concanavalin A-
horseradish peroxidase conjugate (ConA-HRP), medium viscosity
brown seaweed alginate (BSWA) (cat #A2033), and 2,29-azino-
bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) were from
Sigma-Aldrich (St. Louis, MO). BCA assay and AminoLink Plus
Immobilization Kits were from Pierce Biotechnology (Rockford,
IL). Polyclonal goat anti-rabbit HRP conjugate antibody was from
Millipore (Billerica, MA). All other reagents were from Fisher
Scientific (Pittsburgh, PA), unless specifically noted.
Data Analysis
Experiments were conducted in triplicate unless otherwise
noted, and statistical significance was determined using two-tailed
t-tests.
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care & Use
Committee of Dartmouth College (Protocol Number: 07-07-
11CL), and all efforts were made to minimize suffering.
Construction and Cloning of A1-III Encoding Genes
Following the procedure of Hoover and Lubkowski [21],
synthetic genes, codon optimized for expression in E. coli, were
assembled for both the wild type [31] and cysteine point mutant
A1-III enzymes. The genes were appended with a 59-methionine
codon, a 59-FatI restriction site spanning the ATG start, and a 39-
XhoI restriction site immediately following the terminal serine
codon (appends a non-native, C-terminal LeuGlu sequence). Each
point mutant gene encoded a single cysteine substitution at serine
32, alanine 41, alanine 53, alanine 270, or alanine 328 (numbering
as per Yoon et al. [22]). The 1,089 base pair synthetic A1-III genes
were digested with FatI and XhoI, and ligated into NcoI and XhoI
digested pET-28b expression vector resulting in an in frame fusion
with the hexahistidine tag encoded by the plasmid. Ligations were
transformed into electrocompetent DH5alpha [F
2W80lacZDM15
D(lacZYA-argF)U169recA1endA1hsdR17(rK
2mK
+) phoAsupE44 thi-
1gyrA96relA1 l
2], and the identities of the cloned genes were
verified by sequencing plasmid isolated from individual clones.
These plasmid constructs encoded his-tagged wild type (WT-his),
or point mutant A1-III enzymes (S32C-his, A41C-his, A53C-his,
A270C-his, and A328C-his). A gene encoding an untagged version
of the wild type (WT) enzyme was constructed in a similar
manner, but insertion of a dual stop codon (TGATAG) before the
39 restriction site terminated translation prior to the hexahistidine
coding sequence. Sequence verified plasmids were subsequently
transformed into electrocompetent HMS174(DE3) expression
hosts [F
2recA1hsdR(rK12
2 mK12
+) (DE3) (Rif
R)]. The expression
host also bore the pLysS plasmid to repress basal expression.
Protein Expression and Purification
Overnight cultures of expression hosts were grown in LB
supplemented with30 mg/ml kanamycin and 34 mg/ml chloram-
phenicol at 37uC, and then sub-cultured 1:100 into 500 ml of fresh
media. Cultures were grown at 37uC to mid-log, equilibrated to
25uC, and induced with 0.5 mM IPTG for 20 hours. Following
induction, cell cultures were centrifuged at 5000g,4 uC for
10 minutes, pellets were resuspended in 5 ml of native lysis buffer
(50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 8.0),
transferred to a 10 ml Pyrex beaker, and equilibrated on ice for
20 minutes. Cells were disrupted by sonication (Fisher 550 Sonic
Dismembrator). Whole cell lysate was dispensed into 2 ml
eppendorf tubes and centrifuged at 17,000g,4 uC, for 20 minutes.
The supernatant was removed, syringe filtered through a 0.22 mm
PES membrane, and gently mixed with a 0.4 ml bed volume of
Ni-NTA agarose, which had been equilibrated with native lysis
buffer. After binding at 4uC for 1 hour, the column was drained
and washed with 10 bed volumes of wash buffer (50 mM
NaH2PO4, 300 mM NaCl, and 20 mM imidazole pH 8.0).
Purified A1-III was eluted in a native elution buffer (50 mM
NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0), dialyzed
into storage buffer (20mM NaH2PO4 pH 6.5), and kept at 4uC.
The purity of enzyme preparations was typically .95% as assessed
by Coomassie-stained SDS-PAGE gels. Enzyme concentrations
were routinely determined by A280 (NanoDrop 1000, Thermo
Scientific, Waltham, Ma) using a standard curve that had been
independently validated by BCA assay.
For the purpose of immunizing rabbits for antibody production,
the non-tagged native enzyme (WT) was purified as described
previously [32]. Enzyme purity was .99% as assessed by
Coomassie-stained SDS-PAGE gels, and enzyme solutions were
stored in phosphate buffered saline (PBS) at 4uC prior to use.
Covalent Conjugation to PEG
Preliminary optimization studies with the A53C-his point
mutant examined the effects of time (5 minutes to overnight),
temperature (25uCt o3 7 uC), and stoichiometry (1:1 to 20:1
PEG:protein molar ratio) as reaction variables, and it was
ultimately determined that 1 hour reactions at 25uC with a 5:1
molar ratio of PEG:enzyme typically yielded maximal mono-
PEGylated product, i.e. protein molecules each bearing a single
PEG polymer chain. Subsequently, purified A1-III cysteine
mutants were covalently coupled with a 5 molar excess of
20 kDa methoxy-maleimide PEG. PEG was initially solubilized in
DMSO at a concentration of 100 mg/ml, and 12 ml were added to
500 ml of a 1 mg/ml enzyme solution in 20 mM NaH2PO4
pH 6.5. Reactions were incubated at room temperature for
1 hour, and then loaded onto a 120 ml bed volume Superdex 75
size exclusion column. The column was eluted with 150 mM
NaCl, 50 mM NaH2PO4 pH 7.0 at a flow rate of 0.6 ml/min.
Mono-PEGylated A1-III product eluted at ,53 ml. Enzyme
purity was typically .95% as assessed by Coomassie-stained SDS-
PAGE gels, and enzyme solutions were stored at 4uC for later use.
The concentrations of PEGylated enzymes were determined by
A280, as independent experiments demonstrated that conjugation
to the PEG moiety did not alter enzyme molar absorptivity.
Engineered Alginate Lyase-PEG Conjugates
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17042Enzyme Kinetic Analysis
Enzymatic activities were assessed in a 96-well plate format.
Briefly, 5 ml of purified enzyme was added to each of 12
contiguous wells in a UV transparent, 96-well plate (Costar,
Fisher #3635). Using a 12-channel pipette, 195 ml of alginate in
reaction buffer (150 mM NaCl, 50 mM NaH2PO4 pH 7.0) was
simultaneously added to each of the wells. BSWA concentrations
were varied from 0.001% to 0.05% (wt/vol), and each
concentration was assayed in triplicate. The 96-well plates were
immediately transferred to a UV/Vis plate reader (SpectraMax
190, Molecular Devices, Sunnyvale, CA), and product formation
was monitored by measuring absorbance at 235 nm every
15 seconds for 10 minutes. Initial velocities were taken from the
linear portions of the absorbance verses time curves, and Vmax and
Km values were determined by non-linear regression of initial
reaction rates verses substrate concentration. Specific enzyme
activities towards bacterial alginate, purified from P. aeruginosa
FRD1 as described previously [33], were determined in triplicate
at 0.1% (wt/vol) substrate concentration. Assays were carried out
essentially as described above.
IgG Antibody Immunoreactivity
A1-III alginate lyase antiserum was obtained from Covance
Research (Denver, PA). Two New Zealand white rabbits were
initially immunized by subcutaneous injection of 250 mgo f
purified WT A1-III mixed with Freund’s complete adjuvant
(FCA). At twenty day intervals, the rabbits were boosted with
subcutaneous injections of 125 mg of purified WT A1-III mixed
with Freund’s incomplete adjuvant (FIA). Ten days after the first
and fourth boost, serum was collected and antibody titers were
evaluated by determining the serum dilution required to produce a
50% ELISA signal against the WT immunogen. Polyclonal A1-III
specific IgG antibodies were purified from immune serum using an
AminoLink Plus A1-III affinity column prepared from purified
WT-his enzyme as per the manufacturer’s instructions. The
purified primary antibody was aliquoted and stored at 700 mg/ml,
220uC in PBS. ELISAs were performed in high binding 96-well
plates using purified alginate lyase enzymes, polyclonal rabbit IgG
antibody, secondary goat anti-rabbit HRP conjugate and ABTS
for detection. Dose response curves were fit to the data to obtain
EC50 values (half the maximal effective concentration of IgG). All
ELISAs were performed in triplicate. The immunoreactivity of the
PEGylated variants was defined as the ratio of the WT-his EC50 to
the EC50 of the corresponding PEGylated enzyme. Equivalent
binding of the WT-his and PEGylated variants to the 96-well
ELISA plates was verified by activity assays of enzyme solutions
pre- and post-binding. No statistically significant difference in the
fraction of bound enzyme was observed for PEGylated or non-
PEGylated enzymes (data not shown).
Human scFv Antibody Binding Studies
The immunogenicity of WT-his and A53C-his-PEG was
further assessed using an in vitro assay that scores the relative
reactivity of a protein of interest towards a human antibody
fragment library displayed on the surface of yeast
1 [34]. Briefly,
WT-his and A53C-his-PEG were biotinylated as per the
manufacturer’s instructions (Pierce Biotinylation Kit). Magnetic
streptavidin beads (Invitrogen, Carlsbad, CA) were coated
separately with each biotinylated enzyme overnight at 4uC.
WT-his coated beads were combined with A53C-his-PEG coated
beads, and the mixture was incubated with yeast expressing the
human scFv library [25]. Following this binding step, the beads
were magnetically separated and unbound yeast were removed
by aspiration. The remaining bead:yeast mixture was placed in
selective yeast growth media, and the selected yeast cells were
regrown, induced, and selected against pooled beads a second
time. This affinity-selected yeast population was regrown,
induced and then independently incubated for one hour at 4uC
with either WT-his or A53C-his-PEG coated beads. The beads
were magnetically separated, and unbound yeast were aspirated
and discarded. The yeast:bead mixtures were then resuspended in
1 ml of PBS, and a 50 ml aliquot was removed for serial dilution
and plating on selective media to determine the number of yeast
initially bound to each set of beads (‘‘wash 1’’ population). The
remainder of the resuspended yeast:bead mixture was then gently
agitated at 4uC for 15 minutes, and the wash process was
repeated twice more to generate ‘‘wash 2’’ and ‘‘wash 3’’ cell
populations. The number of yeast binders to each protein target
was quantified by plating serial dilutions of each wash population
on selective growth media. Following a 2-day outgrowth, the
number of cfu on each plate were determined and used to back
calculate the total number of bead-bound yeast after each wash
step. These values provide a relative metric for comparing the
immunoreactivity of WT-his and A53C-his-PEG proteins to-
wards a human scFv antibody fragment repertoire.
Following these initial studies, which yielded a relative count of
antibody fragments capable of recognizing each individual
enzyme, the cross-reactivity of yeast isolated against each protein
target was evaluated. This analysis involved regrowth and
induction of the wash 3 yeast populations, and subsequent
magnetic bead selection against both protein targets in parallel.
A more detailed description of the methods for the human scFv
antibody fragment studies is provided as Text S1.
Biofilm Disruption Assays
The capacity of the alginate lyase enzymes to disrupt bacterial
biofilms was assessed in vitro. Briefly, mucoid Xen5 P. aeruginosa
(Caliper Life Sciences, Hopkinton, MA) cultures were grown for
19 hours in 3 ml of TSB media at 37uC. Bacteria were then
subcultured at a 1:5 ratio into fresh TSB media, and 100 ml
aliquots were added in replicate to 96-well plates. Plates were
covered with a gas permeable adhesive strip, and incubated
without shaking for 20 hours at 37uC. Following biofilm growth,
culture media and planktonic bacteria were shaken from the wells,
and the remaining biofilms were rinsed with double distilled water.
The adherent biofilms were treated with 200 ml aliquots of 1 mg/
ml alginate lyase in 20 mM NaH2PO4 pH 6.5. Buffer only was
used as a no treatment control. Each treatment was done in
triplicate. Reactions proceeded at room temperature for 1 hour,
after which enzyme solutions were shaken from the plate, and
wells were again rinsed with double distilled water. Subsequently,
100 ml aliquots of 0.1 mg/ml ConA-HRP were added to all wells.
Blank wells containing no biofilm were used as a background
control. The ConA-HRP lectin was allowed to bind for 1 hour at
room temperature, and the solution was then shaken from the
plate followed by rinsing with double distilled water. Finally,
100 ml of ABTS substrate was added to all wells, and reactions
were incubated for 15 minutes at room temperature before being
quenched with 100 ml of 1% SDS. The absorbance of each well
was measured at 405 nm, background signal from the blank wells
was subtracted from experimental wells, and the percent decrease
in biofilm was calculated by normalizing the signal from enzyme
treated wells to that of wells receiving no enzyme treatment.
Additional experiments directly monitored degraded alginate
reaction products in treated biofilm supernatants, and the resulting
data supported the conclusions drawn from the ConA-HRP lectin
studies.
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Movie S1 Sites of cysteine substitution. Ribbon diagram of
alginate Lyase A1-III (PDB file 1HV6). A trisaccharide reaction
product is bound in the active cleft and shown as a grey ball and
stick model. Amino acid residues targeted for cysteine substitution
are shown in space filling mode, and are color coded as follows:
S32C=Red, A41C=Orange, A53C=Green, A270C=Yellow,
and A328C=Purple.
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Text S1 Human scFv library binding experiments.
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